.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

ZANTAC 150 Drug Profile

« Back to Dashboard
Zantac 150 is a drug marketed by Glaxo Grp Ltd, Glaxosmithkline, and Boehringer Ingelheim. and is included in four NDAs. It is available from five suppliers.

The generic ingredient in ZANTAC 150 is ranitidine hydrochloride. There are forty-two drug master file entries for this compound. One hundred and thirty-seven suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

Summary for Tradename: ZANTAC 150

Patents:0
Applicants:3
NDAs:4
Suppliers / Packagers: see list5
Drug Prices: :see details

Pharmacology for Tradename: ZANTAC 150

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL018703-001Jun 9, 1983RXNo► subscribe► subscribe
Glaxosmithkline
ZANTAC 150
ranitidine hydrochloride
CAPSULE;ORAL020095-001Mar 8, 1994DISCNNo► subscribe► subscribe
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
GRANULE, EFFERVESCENT;ORAL020251-002Mar 31, 1994DISCNNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZANTAC 150

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL018703-001Jun 9, 19834,880,636*PED► subscribe
Glaxosmithkline
ZANTAC 150
ranitidine hydrochloride
CAPSULE;ORAL020095-001Mar 8, 19944,128,658► subscribe
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
GRANULE, EFFERVESCENT;ORAL020251-002Mar 31, 19944,521,431*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZANTAC 150

Drugname Dosage Strength RLD Submissiondate
ranitidine hydrochlorideTablets150 mgZantac 15010/30/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc